Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 20:10:1189017.
doi: 10.3389/fmed.2023.1189017. eCollection 2023.

Preliminary study of anti-CD40 and ubiquitin proteasome antibodies in primary podocytopaties

Natalia Chebotareva  1 , Venzsin Cao  1 , Anatoliy Vinogradov  2 , Igor Alentov  3 , Natalia Sergeeva  3 , Alexey Kononikhin  4 , Sergey Moiseev  1
Affiliations

Preliminary study of anti-CD40 and ubiquitin proteasome antibodies in primary podocytopaties

Natalia Chebotareva et al. Front Med (Lausanne). .

Abstract

Background: Minimal change disease and focal segmental glomerulosclerosis are primary podocytopathies that are clinically presented in adults presenting with severe nephrotic syndrome. The pathogenesis of these diseases is not clear and many questions remain to be answered. A new concept about the role of changes in the antigenic determinant of podocytes and the production of anti-podocyte antibodies that cause podocyte damage is being developed. The aim of the study is to evaluate the levels of anti-CD40 and anti-ubiquitin carboxyl-terminal hydrolase L1 (anti-UCH-L1) antibodies in patients with podocytopathies in comparison with other glomerulopathies.

Methods: One hundred and six patients with glomerulopathy and 11 healthy subjects took part in the study. A histological study revealed primary FSGS in 35 patients (genetic cases of FSGS and secondary FSGS in the absence of NS were excluded), 15 had MCD, 21 - MN, 13 - MPGN, 22 patients - IgA nephropathy. The effect of steroid therapy was evaluated in patients with podocytopathies (FSGS and MCD). The serum levels of anti-UCH-L1 and anti-CD40 antibodies were measured by ELISA before steroid treatment.

Results: The levels of anti-UCH-L1 antibodies were significantly higher in MCD patients and anti-CD40 antibodies were higher in MCD and FSGS than in the control group and other groups of glomerulopathies. In addition, the level of anti-UCH-L1 antibodies was higher in patients with steroid-sensitive FSGS and MCD, and anti-CD40 antibodies were lower than in patients with steroid-resistant FSGS. An increase in anti-UCH-L1 antibody levels above 6.44 ng/mL may be a prognostic factor of steroid-sensitivity. The ROC curve (AUC = 0.875 [95% CI 0.718-0.999]) for response to therapy showed a sensitivity of 75% and specificity of 87.5%.

Conclusion: An increase in the level of anti-UCH-L1 antibodies is specific for steroid-sensitive FSGS and MCD, while an increase in anti-CD40 antibodies - for steroid-resistant FSGS, compared with other glomerulopathies. It suggests that these antibodies could be a potential factor for differential diagnosis and treatment prognosis.

Keywords: FSGS; anti-CD40 antibodies; anti-UCH-L1 antibodies; minimal change disease; podocytopathy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The baseline levels of anti-UCH-L1 antibodies in serum of patients with different glomerulopathies.
Figure 2
Figure 2
The level of anti-CD40 antibodies in the serum of patients with different glomerulopathies.
Figure 3
Figure 3
Anti-UCH-L1 antibodies (A) and anti-CD40 antibodies (B) in patients with different response to corticosteroid therapy. SSNS, steroid-sensitive NS; SRNS, steroid-resistant NS; PR, partial remission.
See this image and copyright information in PMC

References

    1. Haas M, Meehan SM, Karrison TG, Spargo BH. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis. (1997) 30:621–31. doi: 10.1016/S0272-6386(97)90485-6 - DOI - PubMed
    1. Rivera F, López-Gómez JM, Pérez-García R, Spanish Registry of Glomerulonephritis . Clinicopathologic correlations of renal pathology in Spain. Kidney Int. (2004) 66:898–904. doi: 10.1111/j.1523-1755.2004.00833.x - DOI - PubMed
    1. Hommos MS, de Vriese AS, Alexander MP, Sethi S, Vaughan L, Zand L, et al. The incidence of primary vs secondary focal segmental glomerulosclerosis: a clinicopathologic study. Mayo Clin Proc. (2017) 92:1772–81. doi: 10.1016/j.mayocp.2017.09.011 - DOI - PMC - PubMed
    1. Sim JJ, Batech M, Hever A, Harrison TN, Avelar T, Kanter MH, et al. Distribution of biopsy-proven presumed primary glomerulonephropathies in 2000-2011 among a racially and ethnically diverse US population. Am J Kidney Dis. (2006) 68:533–44. doi: 10.1053/j.ajkd.2016.03.416 - DOI - PubMed
    1. Sharma M, Zhou J, Gauchat J, Sharma R, McCarthy ET, Srivastava T, et al. Janus kinase 2/signal transducer and activator of transcription 3 inhibitors attenuate the effect of cardiotrophin-like cytokine factor 1 and human focal segmental glomerulosclerosis serum on glomerular filtration barrier. Transl Res. (2015) 166:384–98. doi: 10.1016/j.trsl.2015.03.002 - DOI - PMC - PubMed